Latest news about Zydus Life Science
Zydus Life Science
1,107.00
+29.30(+2.72%)
Company Performance:
View Company Insights1D+2.72%
1M+21.53%
6M+17.45%
1Y+19.71%
5Y+79.04%
More news about Zydus Life Science
21May 26
Zydus completes Rs 128.83 m investment in Torrent Urja 25
Zydus Lifesciences Limited and its subsidiaries have completed the subscription of equity shares in Torrent Urja 25 Private Limited by investing the remaining Rs. 90.18 million on May 19, 2026. This final tranche, covering Tranches 2, 3, and 4, involved 90,17,848 equity shares and brought the total investment to Rs. 128.83 million for 1,28,82,640 shares. The transaction, executed under Share Subscription and Shareholders’ Agreements, aligns with the company's ESG commitments and carbon neutrality goals.
21May 26
Zydus FY26 net profit rises 11.4%; dividend announced
Zydus Lifesciences Limited announced its audited financial results for the quarter and year ended March 31, 2026, reporting a 16.8% increase in FY26 revenue to Rs. 2,71,484 mn and an 11.4% rise in net profit to Rs. 50,400 mn. The Board recommended a dividend of Re. 1 per equity share and approved a buyback of equity shares for up to Rs. 11,000 mn at Rs. 1,150 per share. Operational highlights included a 20.2% YoY growth in Q4 EBITDA to Rs. 25,544 mn and a 110 basis points expansion in margins to 33.7%.
20May 26
Zydus Life Sets FY27 Targets: High-Teens Revenue Growth, 24%+ EBITDA Margins
Zydus Life has outlined FY27 guidance including high-teens consolidated revenue growth, EBITDA margins above 24%, and total capex of ~INR 1,500 crore, with biosimilars surpassing INR 800 crore. JPMorgan maintains a Neutral rating with a ₹1050 target, upgrading FY27 earnings by 10%, while Jefferies reiterates Buy at ₹1200, raising FY28 EPS estimates by 14% on strong pipeline and US specialty momentum.
20May 26
Zydus Re-appoints Dr. Sharvil Patel as MD for 5 Years
Zydus Lifesciences Limited's board has approved the re-appointment of Dr. Sharvil P. Patel as Managing Director for five years starting April 1, 2027, and the appointment of Mr. Kulin S. Lalbhai as an Independent Director for five years starting May 19, 2026. Both appointments require shareholder approval at the next Annual General Meeting.
20May 26
Zydus Sets July 24 Record Date for FY26 Dividend
Zydus Lifesciences has fixed July 24, 2026, as the record date to determine shareholder eligibility for a final dividend of Re. 1 per share for FY26. The dividend is subject to shareholder approval at the AGM scheduled for August 11, 2026, with payment expected around August 14. The company previously reported a consolidated net profit of INR 50,400 million for FY26.
14May 26
Zydus Worldwide DMCC to Acquire Entire Stake in Assertio Holdings for USD 166.4 Million
Zydus Lifesciences' subsidiary Zydus Worldwide DMCC has signed a definitive agreement to acquire all outstanding shares of Nasdaq-listed Assertio Holdings for approximately USD 166.4 million at USD 23.50 per share in cash. The deal strengthens Zydus's U.S. specialty oncology presence through Assertio's primary asset ROLVEDON®, which recorded USD 68.23 million in turnover in 2025, and its 170+ community oncology accounts. The transaction, expected to close in FY2026-27, will result in Assertio being delisted from Nasdaq.
14May 26
Zydus Lifesciences Independent Director Apurva S. Diwanji Ceases Post Upon Tenure Completion
Zydus Lifesciences Limited disclosed that Mr. Apurva S. Diwanji (DIN: 00032072) ceased as Director, including Independent Director, effective May 12, 2026, following completion of his tenure. The company filed the requisite disclosure with BSE and NSE on May 13, 2026, and acknowledged Mr. Diwanji's contributions, dedication, and professional expertise during his tenure.
14May 26
Zydus Lifesciences GST Appeal Order Upholds Rs. 10.12 Million Penalty
Zydus Lifesciences Limited received an Appeal Order from the Central GST Appeals Commissionerate, Chandigarh, upholding a demand of Rs. 1.71 million and penalty of Rs. 10.12 million related to a GST audit covering July 2017 to March 2021. The order, passed under section 107 of the CGST Act, 2017, alleges excess or wrongful input tax credit availed by the company. Zydus intends to file a second appeal before GSTAT and has confirmed no material financial impact on its operations.
06May 26
USFDA Inspects Zydus Lifesciences' Biologics Injectable Plant in Ahmedabad; Reports 7 Observations
The USFDA completed a GMP surveillance inspection at Zydus Lifesciences' Unit 9 Biologics Injectable facility at Zydus Biotech Park, Changodar, Ahmedabad, covering the period April 27 to May 5, 2026. The inspection concluded with seven observations, with no data integrity-related observations recorded. Zydus Lifesciences has committed to working closely with the USFDA to address the observations expeditiously.
05May 26
Zydus Lifesciences Subsidiary ZVTEC Receives CGST Demand Order of Rs. 9.00 Million for Alleged Inadmissible Input Tax Credit
Zydus VTEC Limited (ZVTEC), a wholly owned subsidiary of Zydus Lifesciences Limited, received a CGST demand and penalty order of Rs. 9.00 million each from the Deputy Commissioner of CGST & Central Excise, Ahmedabad North Commissionerate, on May 4, 2026. The order, passed under Section 74 of the CGST Act, 2017, relates to alleged inadmissible Input Tax Credit availment for the period September 2020 to March 2023. Zydus Lifesciences has stated its intention to appeal the order and confirmed there is no material financial impact on ZVTEC or the company.
02May 26
Zydus Lifesciences Completes €360,000 Acquisition of French Orthopedic Firm
Zydus Lifesciences has completed the €360,000 acquisition of French orthopedic company Aptitude Orthopedie through subsidiary Amplitude SAS. The target company, incorporated in 2016, specializes in medical equipment distribution with €364,000 turnover in FY2025. The strategic acquisition aims to internalize commercial capabilities and eliminate third-party commission fees.
02May 26
Zydus Subsidiary Completes Euro 700,000 Acquisition of French Medical Distributor
Zydus Lifesciences announced the completion of its subsidiary Amplitude SAS's acquisition of FBC Medical, a French medical equipment distributor, for Euro 700,000. The transaction involves 100% share capital acquisition of the company incorporated in 2016, which has maintained consistent turnover of around Euro 935,000. The strategic acquisition aims to internalize commercial capabilities and reduce long-term selling and distribution costs by eliminating third-party commission fees.
01May 26
Zydus Lifesciences Incorporates Wholly Owned US Subsidiary Zara Merger SUB Inc.
Zydus Lifesciences has incorporated Zara Merger SUB Inc. as a wholly owned subsidiary in the United States on April 24, 2026. The new entity is authorized to issue 1,000 common stock with a par value of USD 0.001 per share and will serve internal group restructuring purposes. The company disclosed this information under Regulation 30 of SEBI Listing Obligations.
27Apr 26
Zydus Receives DCGI Approval for Phase III Trials of Anti-Malarial Zintrodiazine
Zydus Lifesciences has secured DCGI approval to conduct two Phase III clinical trials for Zintrodiazine, a novel anti-malarial drug candidate active against drug-resistant P. falciparum and P. vivax strains. The trials will enroll 651 patients for P. falciparum and 390 patients for P. vivax malaria, evaluating efficacy through PCR-adjusted ACPR as the primary endpoint. This development builds on a 2016 collaboration with Medicines for Malaria Venture to create alternatives to artemisinin-based therapies, with over 1,80,000 malaria cases reported in India last year.
23Apr 26
Zydus Lifesciences Publishes Official Notice for 'Saksham Niveshak' Campaign
Zydus Lifesciences has published the official notice for its second 100-day 'Saksham Niveshak' campaign in Financial Express and communicated the publication to BSE and NSE. The campaign runs from April 1-July 9, 2026, targeting shareholders with unpaid dividends and encouraging KYC updates to prevent IEPF transfer.
16Apr 26
Zydus Lifesciences Receives USFDA Approval for Oncology Injectable Facility
Zydus Lifesciences has secured USFDA approval for its oncology injectable manufacturing facility in SEZ1, Ahmedabad, following a successful Pre-Approval Inspection conducted in November 2025. The approval covers the new isolator injectable line and positions the company to manufacture specialized oncology products for the US market while meeting stringent regulatory requirements.
15Apr 26
Zydus Lifesciences Subsidiary Wins GST Appeal, Rs. 1.66 Million Penalty Dropped
Zydus Lifesciences Limited announced that its subsidiary German Remedies Pharmaceuticals Private Limited has successfully appealed against a GST penalty of Rs. 1.66 million imposed for FY 2018-19. The Office of Commissioner, Central GST, Appeal Ahmedabad Commissionerate dropped the entire penalty amount related to alleged excess availment of Input Tax Credit. The company confirmed no material impact on financials or operations from this favorable outcome.
10Apr 26
Zydus Lifesciences Receives ESG Rating of 68 from ESGRAIL, Up from 66 Last Year
Zydus Lifesciences Limited disclosed receiving an ESG rating of 68 from SEBI-registered provider ESGRAIL, improving from last year's rating of 66. The rating was independently prepared without company engagement, based on publicly available information. The company made this disclosure under SEBI Regulation 30 compliance requirements, with the report received on April 9, 2026.
09Apr 26
Zydus Lifesciences Submits Q4 FY26 Compliance Certificate Under SEBI Depositories Regulations
Zydus Lifesciences Limited filed its quarterly compliance certificate under SEBI regulation 74(5) for Q4 FY26, confirming proper dematerialization procedures for equity shares. The certificate, submitted on April 8, 2026, verifies that physical certificates were mutilated and cancelled after due verification, with depositories substituted as registered owners. MUFG Intime India Private Limited, the company's RTA, confirmed all procedures were completed within prescribed timelines.
08Apr 26
Zydus Life Sciences Receives Final USFDA Approval for Dapagliflozin Tablets
Zydus Life Sciences has secured final USFDA approval for Dapagliflozin tablets in 5mg and 10mg strengths, gaining 180 days of shared generic drug exclusivity. The SGLT2 inhibitor for type 2 diabetes management will be manufactured at the company's SEZ facility in Ahmedabad and targets a substantial market with annual sales of $10.20 billion.
07Apr 26
Zydus Lifesciences Gets Relief as Rs. 41.77 Million GST Demand Dropped
Zydus Lifesciences Limited received a favorable order dated March 24, 2026, from the Adjudication Authority, Gandhinagar, GST Department, dropping a Rs. 41.77 million GST demand for FY 2019-20. The company made this disclosure voluntarily as good governance practice, clarifying it's not material under SEBI regulations. While celebrating this relief, the pharmaceutical company continues to face a separate Rs. 14.20 million GST demand covering FY 2019-20 to 2023-24, which it plans to contest through appeal.
31Mar 26
Zydus Lifesciences announces transition of Mr. Mayank Satpal from Senior Management due to organizational realignment
Zydus Lifesciences Limited announced that Mr. Mayank Satpal has transitioned from Senior Management effective March 31, 2026, due to organizational realignment. The company informed stock exchanges under Regulation 30 of SEBI Listing Regulations about this management change. Mr. Satpal will continue as part of the leadership team despite the transition from Senior Management. The change is attributed to realignment of organizational reporting structure rather than a complete departure from the company.
25Mar 26
Zydus Lifesciences Receives Rs. 3.28 Cr Tax Demand Order from Gujarat Authorities for FY 2019-20
Zydus Lifesciences Limited has received a Rs. 3.28 Cr tax demand order from the Assistant Commissioner of State Tax, Gujarat, for alleged inadmissible Input Tax Credit availment during FY 2019-20. The order was received on March 24, 2026, under section 74 of the CGST Act, 2017, and includes principal amount, interest, and penalty. The company plans to appeal the order, expressing confidence in its legal position based on past High Court and Supreme Court precedents, and expects no material financial impact on its operations.
21Mar 26
Zydus Lifesciences Launches Semaglutide Injection with Innovative Reusable Multi-Dose Pen Device
Zydus Lifesciences has officially launched its Semaglutide injection in India with DCGI approval for Type 2 Diabetes and obesity treatment. The product features an innovative reusable multi-dose pen device and will be marketed under three brand names at approximately Rs. 2,200 monthly cost, addressing India's growing diabetes and obesity health challenges.
19Mar 26
Zydus Lifesciences Launches Aerolife Mini™ Foldable Inhaler For Enhanced Drug Delivery
Zydus Lifesciences has introduced Aerolife Mini™, India's first portable and foldable spacer device for respiratory care, addressing the critical challenge of suboptimal inhaler technique that affects 94% of patients. The device features compact, ready-to-use design that enhances drug delivery to lungs and improves patient adherence through greater convenience and portability.
18Mar 26
Zydus Lifesciences Strengthens Semaglutide Market Strategy with Torrent Partnership
Zydus Lifesciences has strengthened its semaglutide injection market strategy by adding Torrent Pharma as a co-marketing partner alongside its existing Lupin collaboration. The March 18, 2026 licensing agreement with Torrent provides semi-exclusive rights to market the innovative 15 mg/3 ml formulation under the SEMBOLIC™ brand, complementing Zydus's own SEMAGLYN™, MASHEMA™, and ALTERME™ brands and Lupin's Semanext® and Livarise® products.
16Mar 26
Zydus Lifesciences: SentyNL Therapeutics Signs Deal With PRG S&T To License Molecule For Hutchinson-Gilford Progeria Syndrome
Sentynl Therapeutics Inc., a wholly-owned subsidiary of Zydus Lifesciences Limited, has entered into a strategic licensing agreement with Korean rare disease specialist PRG S&T to acquire rights to investigational drug candidate Progerinin (SLC-D011) for treating Hutchinson-Gilford Progeria Syndrome. The drug has received FDA orphan drug designation and is currently finalizing a Phase 2A clinical trial, with data expected before the end of the first half of 2026.
16Mar 26
Zydus Lifesciences' Desidustat Receives NMPA Approval for Renal Anaemia Treatment in China
Zydus Lifesciences achieved a major regulatory milestone with NMPA approval for Desidustat tablets in China for treating renal anaemia. The innovative HIF-PHI drug is exclusively licensed to China Medical System Holdings Limited and addresses substantial market opportunities with over 120 million CKD patients in China.
13Mar 26
Zydus Lifesciences Receives Final USFDA Approval for Cevimeline Hydrochloride Capsules
Zydus Lifesciences has secured final USFDA approval for Cevimeline Hydrochloride Capsules 30mg, indicated for treating dry mouth associated with Sjögren's syndrome. The product, to be manufactured at the company's SEZ-II facility in Ahmedabad, has projected annual sales of USD 26.9 million and expands Zydus' regulatory portfolio to 436 approvals.
12Mar 26
Zydus Lifesciences Launches AI-Powered Continuous Glucose Monitors Diasens™ and GlucoLive™
Zydus Lifesciences Limited launched Diasens™ and GlucoLive™, AI-powered continuous glucose monitoring devices designed for diabetic, CKD, and post-transplant patients. The devices automatically stream readings every three minutes to smartphones without manual scanning, partnering with TatvaCare's GoodFlip™ app for comprehensive digital health management. This addresses India's significant diabetes burden of over 101 million adults, moving beyond episodic monitoring to continuous, AI-enhanced glucose surveillance with remote clinician oversight.
28Feb 26
Zydus Lifesciences Receives USFDA Final Approvals for Ivermectin and Dapsone Tablets
Zydus Lifesciences Limited received final USFDA approvals on February 28, 2026, for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP in 25 mg and 100 mg strengths. The products target annual US markets worth USD 14.8 million and USD 8.4 million respectively, with manufacturing planned at Ahmedabad facilities and distribution through Viona Pharmaceuticals Inc. These approvals bring the company's total USFDA approvals to 434, with 505 ANDAs filed since FY 2003-04.
27Feb 26
Zydus Lifesciences Completes Pivotal Study for Pembrolizumab Biosimilar FYB206
Zydus Lifesciences announced successful completion of the pivotal Dahlia pharmacokinetic study for FYB206, a pembrolizumab biosimilar in-licensed from Formycon AG for U.S. and Canadian markets. The study demonstrated bioequivalence to Keytruda, completing the clinical data package and clearing the pathway for near-term USFDA BLA filing in the immuno-oncology biosimilar market.
26Feb 26
Zydus Lifesciences Announces Day 1 Semaglutide Launch with Innovative Pen Device
Zydus Lifesciences announces strategic Day 1 patent expiry launch of Semaglutide injection in India featuring innovative reusable pen delivery system. The company will market the diabetes and obesity treatment under three brands with DCGI approval, addressing India's significant health burden of 8.9 crore diabetic adults.
19Feb 26
Zydus Lifesciences Injectable Plant Passes USFDA Inspection with Zero Observations
Zydus Lifesciences Limited successfully completed a USFDA Pre Approval Inspection at its Injectable Medical Devices facility in Ahmedabad with NIL observations. The inspection was conducted from February 16-19, 2026, at the company's Unit 9 facility located at Zydus Biotech Park, Changodar. This positive regulatory outcome demonstrates compliance with USFDA manufacturing standards and was disclosed under SEBI Regulation 30 requirements.
19Feb 26
Zydus Lifesciences Receives USFDA Final Approval for Bosentan Tablets for Pediatric PAH Treatment
Zydus Lifesciences Limited has received final USFDA approval for Bosentan tablets for oral suspension, 32 mg, a generic version of Tracleer® indicated for treating Pulmonary Arterial Hypertension in children aged 3 years and older. The dual endothelin receptor antagonist targets a USD 9.3 mn annual US market and will be manufactured at the company's SEZ, Ahmedabad facility. This approval brings Zydus's total USFDA approvals to 432, with 505 ANDAs filed since FY 2003-04, strengthening its presence in the specialized pediatric pharmaceutical segment.
19Feb 26
Zydus Lifesciences Launches India's First Indigenous Aflibercept Biosimilar ANYRA™
Zydus Lifesciences Limited launched ANYRA™, India's first indigenously developed Aflibercept 2 mg biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer. The biosimilar treats multiple retinal conditions including neovascular AMD, diabetic retinopathy, and retinal vein occlusions, addressing the needs of millions of Indian patients affected by these vision-threatening diseases. With India hosting over 100 million diabetics and millions suffering from retinal disorders, ANYRA™ enhances access to affordable anti-VEGF therapy. Zydus maintains India's largest biosimilar portfolio with more than 13 biosimilars developed and manufactured domestically.
17Feb 26
Zydus Lifesciences Launches PEPAIR™, India's First Affordable Drug-Free Respiratory Device at Rs. 990
Zydus Lifesciences has launched PEPAIR™, India's first affordable OPEP device priced at Rs. 990, targeting over 90 lakh patients with chronic respiratory conditions. The drug-free, handheld device features a patented 3-resistance system designed to improve breathing in COPD, asthma, and bronchiectasis patients. Developed in partnership with AeroDel Technology Innovations, the launch strengthens Zydus's position as a leading respiratory player in India.
15Feb 26
Zydus Lifesciences Q3FY26 Results and Earnings Call Highlight Strategic Growth
Zydus Lifesciences delivered strong Q3FY26 performance with consolidated revenue of ₹68,645 million (30.30% YoY growth) and net profit of ₹10,421 million. The company held its post-results earnings call on February 10, 2026, where management discussed strategic initiatives including the upcoming Saroglitazar USFDA filing for PBC indication, biosimilar partnerships for Pembrolizumab and Ranibizumab, and the successful launch of Zycubo for Menkes disease treatment. All key business segments showed robust growth with North America up 16%, India branded formulations up 14%, and international markets growing 38% year-on-year.
14Feb 26
Zydus Lifesciences Receives USFDA Final Approval for Ammonium Lactate Cream, 12%
Zydus Lifesciences Limited has received final USFDA approval for Ammonium Lactate Cream, 12%, a topical prescription medication for dry skin conditions including xerosis and ichthyosis vulgaris. The product will be manufactured at the company's Changodar facility and distributed by Viona Pharmaceuticals Inc. With annual US sales of USD 15 mn, this approval brings Zydus's total USFDA approvals to 430 out of 505 ANDAs filed since FY 2003-04.
12Feb 26
Zydus Lifesciences Settles US Patent Dispute with Astellas for USD 120 Million
Zydus Lifesciences Limited has settled its US patent litigation with Astellas Pharma Inc. over Myrbetriq (Mirabegron) for USD 120 million plus ongoing licensing fees until September 2027. The settlement concludes all legal disputes between the companies and allows Zydus to continue marketing its generic Mirabegron in the United States. This resolution follows the company's earlier intimation about the patent litigation dated April 17, 2025.
09Feb 26
Zydus Lifesciences Board Reviews Exchange Penalties for Technical Non-Compliance with Meeting Intimation Rules
Zydus Lifesciences Limited's board reviewed penalties of ₹11,800 each from BSE and NSE for technical non-compliance with Regulation 29 regarding board meeting intimation. The issue arose from different holiday calendar interpretations between Ahmedabad (company's location) and Mumbai (exchanges' location) for a November 6, 2025 meeting. The board acknowledged the inadvertent error, confirmed penalty payments, and committed to strengthened compliance processes.
31Jan 26
Zydus Lifesciences Announces Superannuation of Senior Vice President Corporate Affairs
Zydus Lifesciences Limited announced the superannuation of Mr. Manoj Kumar Kamra, Senior Vice President-Corporate Affairs, effective January 31, 2026. The disclosure was made under Regulation 30 of SEBI listing regulations and related circulars, with formal communication filed to BSE and NSE by Company Secretary Dhaval N. Soni.
27Jan 26
Zydus Lifesciences Schedules Board Meeting on February 9, 2026 for Q3FY26 Financial Results
Zydus Lifesciences Limited has scheduled its Board of Directors meeting for Monday, February 9, 2026, to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025. The company has notified both BSE and NSE in compliance with SEBI Regulation 29(1), and implemented a trading window closure for Directors and Designated Persons until February 11, 2026, with trading resuming on February 12, 2026.
23Jan 26
Zydus Lifesciences USFDA Inspection at Ankleswar Plant Concludes with 3 Observations
Zydus Lifesciences Limited completed a USFDA inspection at its Unit-2 manufacturing plant in Ankleswar, Gujarat, from January 19-23, 2026. The inspection concluded with 3 observations, with no data integrity related issues identified. The company has committed to working closely with the USFDA to address the observations expeditiously and made this disclosure under SEBI Regulation 30 requirements.
20Jan 26
Zydus Lifesciences ESG Rating Improved to 84/100 by S&P Global
Zydus Lifesciences Limited announced that S&P Global has revised its Corporate Sustainability Assessment ESG Score from 83/100 to 84/100 for 2025. The company had initially received the 83/100 rating in December 2025, which has now been upgraded by one point. This improvement reflects enhanced performance in environmental, social, and governance criteria as assessed by S&P Global's sustainability evaluation framework.
15Jan 26
Zydus Lifesciences Completes Agenus Acquisition, Establishes Zylidac Bio LLC for US Biologics Manufacturing
Zydus Lifesciences Limited completed its strategic acquisition of Agenus Inc.'s biologics manufacturing facilities and equity stake on January 15, 2026, following CFIUS and regulatory approvals. The transaction establishes Zylidac Bio LLC as a US-based CDMO subsidiary operating facilities in Emeryville and Berkeley, California, while securing exclusive manufacturing rights for Agenus' Phase 3 immuno-oncology candidates and commercialization rights in India and Sri Lanka.
15Jan 26
Zydus Lifesciences Receives USFDA Final Approval for Eltrombopag Tablets
Zydus Lifesciences announced on January 15 that it secured final USFDA approval for Eltrombopag Tablets in four different strengths for treating thrombocytopenia. The approval targets a significant USD 1262.50 million US market opportunity, with manufacturing planned at the company's SEZ facility in Ahmedabad, bringing their total USFDA approvals to 429 out of 505 filed ANDAs since FY 2003-04.
13Jan 26
Zydus Lifesciences Receives FDA Approval for ZYCUBO, First Treatment for Rare Menkes Disease
Zydus Lifesciences achieved a major regulatory milestone with FDA approval of ZYCUBO for Menkes disease treatment through its US subsidiary Sentynl Therapeutics. This represents the first approved therapy for the rare genetic condition in the United States. Clinical trials showed 177.1 months median survival for early treatment versus 17.6 months for untreated patients, demonstrating nearly 80% reduction in death risk.
10Jan 26
Zydus Lifesciences Dissolves French Subsidiary Ampliman 2 Without Business Impact
Zydus Lifesciences Limited dissolved its French subsidiary Ampliman 2 effective January 9, 2026, without liquidation. All assets and liabilities were transferred to parent company Zydus MedTech (France) S.A.S. The pharmaceutical company confirmed this restructuring will not impact business operations, representing a streamlining of its European subsidiary structure.
02Jan 26
Zydus Lifesciences Dissolves Luxembourg Subsidiary Auroralux S.A.S. Effective December 31, 2025
Zydus Lifesciences has announced the dissolution of its wholly owned subsidiary Auroralux S.A.S., Luxembourg, effective December 31, 2025, without liquidation. All assets and liabilities will be transferred to Zydus MedTech (France) S.A.S., ensuring business continuity with no operational impact.
30Dec 25
Zydus Lifesciences Receives ₹2.8 Crore GST Demand Order for FY 2018-19
Zydus Lifesciences Limited received a ₹2.8 crore GST demand order from Gujarat tax authorities for alleged inadmissible Input Tax Credit availment during FY 2018-19. The order was issued under section 74 of CGST Act, 2017, and received on December 29, 2025. The company plans to appeal the decision, citing favorable precedents from higher courts, and maintains there will be no material financial impact on operations.
24Dec 25
Zydus Lifesciences Further Extends Sterling Biotech API Acquisition to June 2026
Zydus Lifesciences has announced a second extension for its Sterling Biotech API business acquisition, moving the deadline to June 30, 2026. The extension follows ongoing processes at Sterling Biotech to complete conditions precedent outlined in the Business Transfer Agreement originally signed in September 2024.
24Dec 25
Zydus Partners with Bioeq for US Biosimilar Rights to NUFYMCO
Zydus Lifesciences has formed a strategic partnership with Swiss biopharmaceutical company Bioeq AG for the commercialisation of NUFYMCO, an interchangeable biosimilar to Lucentis (Ranibizumab) in the US market. The collaboration involves Zydus handling commercialisation while Bioeq manages development, manufacturing and supply, targeting a $210 million market opportunity with FDA approval confirmed on December 18, 2025.
23Dec 25
High Court Permits Zydus Lifesciences to Manufacture and Export Semaglutide
Zydus Lifesciences has received High Court permission to manufacture semaglutide, a medication used for diabetes treatment and weight management. The court order also allows the company to export the drug to specific international markets. This regulatory approval enables Zydus to enter semaglutide production for both domestic and select international markets, potentially expanding its presence in the diabetes care and weight management sectors.
19Dec 25
Zydus Signs Exclusive Agreement with Myriad Genetics for Cancer Testing in India
Zydus Lifesciences Limited has entered into an exclusive partnership with US-based Myriad Genetics to introduce advanced cancer-risk assessment diagnostic tests in India. The agreement covers three key tests: MyRisk Hereditary Cancer Test analyzing 63 genes for hereditary cancer risk, MyChoice HRD Plus Test for ovarian cancer treatment decisions, and Prolaris Test for prostate cancer prognosis, marking a significant expansion in precision oncology services for Indian patients.
16Dec 25
Zydus Lifesciences ESG Score Improves to 69.4, Mourns Senior Executive Loss
Zydus Lifesciences has received an enhanced ESG score of 69.4 for FY25 from SES ESG Research, improving from the previous year's 67.8, maintaining its Medium Risk category. The company also announced the passing of Mr. Samir Desai, President-BU Biologics, ensuring regulatory compliance through timely disclosures to stock exchanges.
16Dec 25
Zydus Lifesciences: Sentynl Therapeutics Gets FDA Acceptance for CUTX-101 NDA
Zydus Lifesciences announced that Sentyln Therapeutics received FDA acceptance for CUTX-101 NDA resubmission targeting Menkes disease treatment, with a PDUFA date of January 14, 2026. The investigational therapy demonstrated significant clinical efficacy with 80.00% reduction in death risk and could become the first approved treatment for this rare pediatric genetic condition.
12Dec 25
Zydus Lifesciences Secures 99.89% Shareholder Approval for ₹5,000 Crore Fundraising
Zydus Lifesciences achieved a decisive 99.89% shareholder approval for its ₹5,000 crore fundraising initiative through postal ballot voting conducted on December 12, 2025. The approved framework allows flexible fund raising through various instruments including equity shares, convertible securities, and debentures via methods like QIP, rights issue, and preferential allotment. Additionally, the company received its first NMPA approval in China for Venlafaxine ER Capsules, marking a significant milestone in its international expansion strategy.
12Dec 25
Zydus Life Sciences Announces Postal Ballot Voting Results for Special Resolution
Zydus Life Sciences Limited completed its postal ballot voting process for a special resolution on December 12, 2025, with remote e-voting conducted through CDSL from November 13 to December 12, 2025. The company reported voting results across different shareholder categories and submitted compliance documents to BSE and NSE under SEBI Listing Regulations.
10Dec 25
Zydus Lifesciences Launches Bone Health Drug Zyrifa For Cancer Patients At ₹12,495
Zydus Lifesciences has launched Zyrifa, a specialized bone health medication priced at ₹12,495 designed to prevent skeletal complications in cancer patients. The launch strengthens the company's oncology portfolio and demonstrates its commitment to addressing critical healthcare needs in cancer treatment.
10Dec 25
Zydus Lifesciences Partners with Formycon for Exclusive Biosimilar Keytruda Deal in North America
Zydus Lifesciences has formed an exclusive partnership with Formycon for licensing and supply of a biosimilar to Keytruda in the US and Canada. This strategic collaboration strengthens the company's biosimilar portfolio and expands its presence in key North American pharmaceutical markets. The partnership provides exclusive access to advanced biosimilar technology for one of the most significant oncology treatments.
04Dec 25
Zydus Lifesciences' Jarod Injectable Facility Receives USFDA Inspection Report
Zydus Lifesciences' Jarod Injectable Facility has received a 'Voluntary Action Indicated' (VAI) classification from the USFDA following a Good Manufacturing Practices inspection. The VAI status indicates minor deficiencies that require attention but allows continued operations. Zydus is expected to address these concerns voluntarily, demonstrating its commitment to maintaining high-quality manufacturing standards.
25Nov 25
Zydus Lifesciences Secures USFDA Approval for Cardiac Medication
Zydus Lifesciences has obtained final approval from the U.S. FDA for its Verapamil Hydrochloride Extended-Release Tablets, a medication used to treat cardiac conditions. This approval allows Zydus to market and distribute the product in the United States, expanding its product portfolio and strengthening its position in the U.S. pharmaceutical market. Verapamil Hydrochloride is a calcium channel blocker used for treating high blood pressure, chest pain, and certain heart rhythm disorders.
19Nov 25
Zydus Foundation Loses Wholly-Owned Subsidiary Status Following Share Allotment
Zydus Life Science announced that its wholly-owned subsidiary, Zydus Foundation, has ceased to hold that status following a preferential share allotment. On November 19, 2025, Zydus Foundation issued 4,50,000 equity shares to Ramanbhai Foundation, a public charitable trust. Zydus Life Science now retains 50,000 equity shares in Zydus Foundation. The transaction was conducted at fair value, determined by a SEBI-registered valuer, and on an arm's length basis. The financial impact on Zydus Life Science appears minimal, with no contribution to income or net worth for the fiscal year ending March 31, 2025.
14Nov 25
Zydus Lifesciences Expands Oncology Portfolio with FDA Approval for Prostate Cancer Drug
Zydus Life Science has obtained final USFDA approval for Leuprolide Acetate Injection, used in the palliative treatment of advanced prostatic cancer. The drug, with estimated annual U.S. sales of $69.00 million, will be manufactured at Zydus' oncology injectable facility in Ahmedabad. This approval marks Zydus' 427th USFDA approval, strengthening its oncology portfolio and U.S. market presence.
14Nov 25
Zydus Lifesciences: CE Mark for Surgical Robot, USFDA Approval for MS Drug, and FDA Inspection of Oncology Facility
Zydus Life Science has received CE mark approval for its robotic surgical system 'Andy', USFDA approval for Diroximel Fumarate Delayed-Release Capsules to treat multiple sclerosis, and completed a US FDA inspection at its oncology injectable facility. The 'Andy' system combines navigation technology with robotic assistance for orthopaedic surgeries. The multiple sclerosis treatment has expected annual sales of $999.40 million in the US. The FDA inspection resulted in two observations with no data integrity issues.
13Nov 25
Zydus Lifesciences Reports Robust Q2 FY26 Performance with 17% Revenue Growth
Zydus Life Science reported robust Q2 FY26 results with consolidated revenues of Rs 61.20 billion, up 17% year-on-year. EBITDA margin improved to 32.90%, with EBITDA and net profit both up 38%. US formulations business grew 14%, India branded formulations increased 9%, international markets surged 39%, and consumer wellness rose 31%. Key developments include specialty portfolio expansion, international acquisition of Comfort Click Limited, launch of India's first trivalent influenza vaccine, positive clinical trial results for Saroglitazar Magnesium, and acquisition of Amplitude Surgical.
11Nov 25
Zydus Lifesciences Secures Maiden NMPA Approval in China for Antidepressant Medication
Zydus Lifesciences has received approval from China's National Medical Products Administration (NMPA) for Venlafaxine Extended-Release Capsules in 75mg and 150mg strengths. This marks the company's first entry into the Chinese pharmaceutical market through the NMPA regulatory pathway. Venlafaxine, an antidepressant in the serotonin-norepinephrine reuptake inhibitor (SNRI) class, is used to treat major depressive disorder and anxiety disorders. The approval opens up opportunities for Zydus in one of the world's largest healthcare markets, potentially strengthening its global position.
07Nov 25
Zydus Lifesciences Reports Strong Q2 FY26 Performance, Maintains FY26 Growth Targets and Receives Tentative USFDA Approval for Olaparib Tablets
Zydus Life Science reported robust Q2 FY26 results with revenue up 17% to ₹61,232 million and net profit up 38% to ₹12,586 million. The company saw growth across all segments, with US Formulations up 13.5%, India Formulations up 8.4%, Consumer Wellness up 30.7%, and International Markets up 39.4%. Zydus completed acquisitions of Amplitude Surgical SA and Comfort Click Limited, expanding its medical devices and wellness portfolios. The company also received tentative USFDA approval for Olaparib tablets and reported positive results for Saroglitazar Magnesium in PBC trials.
06Nov 25
Zydus Lifesciences Reports Growth in US Formulations and Advances in Beta-Thalassemia Treatment
Zydus Life Science announced a 13.5% growth in its US formulations business. The company's novel oral treatment, Desidustat, received Orphan Drug Designation from the FDA for beta-thalassemia treatment. This designation offers potential benefits including market exclusivity, financial incentives, and development support. Desidustat, a HIF-prolyl hydroxylase inhibitor, shows promise in increasing hemoglobin and red blood cell counts, potentially improving life quality for beta-thalassemia patients.
06Nov 25
Zydus Lifesciences Reports Strong Q2 Growth with 38% EBITDA Jump and Board Approves ₹5,000 Crore Fundraising Plan
Zydus Lifesciences reported impressive Q2 financial results with revenue increasing 16.41% YoY to ₹6,100.00 crore. EBITDA grew 38.01% to ₹2,015.00 crore, and EBITDA margin expanded by 5.01 percentage points to 32.92%. The company's board has approved a fundraising plan of up to ₹5,000.00 crores through various securities, subject to approvals.
05Nov 25
Zydus Life Sciences Secures FDA Approval for Ahmedabad Manufacturing Facility
Zydus Life Sciences' SEZ-II manufacturing facility in Ahmedabad successfully passed a U.S. FDA Pre-Approval Inspection from August 11-14, 2025, receiving zero observations and a 'No Action Indicated' (NAI) classification. The company also received tentative USFDA approval for Budesonide delayed-release capsules on November 4, 2025. As of September 30, 2025, Zydus has 425 ANDA approvals and has filed 487 ANDAs since FY 2003-04.
01Nov 25
Zydus Lifesciences Faces ₹74.23 Crore IGST Demand, Plans to Appeal
Zydus Lifesciences has received a tax demand of ₹74.23 crores from Indian authorities for alleged excess IGST refund claims on exports from April 2018 to March 2024. The order, issued by the Joint Commissioner of Common Adjudication Authority CGST in Ahmedabad, Gujarat, covers four GST registrations across different states. The company plans to challenge the order, stating it has no material financial impact. The dispute centers on the use of CIF value instead of FOB value for export calculations.
29Oct 25
Zydus Lifesciences Secures USFDA Approval for Baddi Manufacturing Plant
Zydus Lifesciences' Baddi manufacturing facility has received approval from the U.S. Food and Drug Administration (USFDA) with a Voluntary Action Indicated (VAI) classification. The USFDA conducted an inspection at the facility from August 4 to August 13, and the company has received the Establishment Inspection Report (EIR), concluding the inspection as closed. This approval strengthens Zydus Lifesciences' position in the pharmaceutical market, particularly for products destined for the U.S. market.
26Oct 25
Zydus Lifesciences Completes 100% Acquisition of Amplitude Surgical SA
Zydus Lifesciences has finalized its acquisition of French company Amplitude Surgical SA through its subsidiary Zydus MedTech France SAS. The process, which began in July 2025 with an 85.60% stake, concluded on October 24, 2025, with the acquisition of the remaining 14.40% share capital and voting rights. This strategic move strengthens Zydus's position in the European medical technology market, particularly in lower-limb orthopedics. The company informed stock exchanges of this development, citing a slight delay due to Diwali holidays.
24Oct 25
Zydus Lifesciences Secures Health Canada Approval for Generic Mesalamine Suppositories
Zydus Life Science received a Notice of Compliance from Health Canada for its generic Mesalamine suppositories 1000 mg, used to treat ulcerative proctitis. The annual sales of Mesalamine suppositories in Canada are 4.86 million Canadian dollars. The medication will be manufactured at Zydus's facility in Changodar, Ahmedabad, Gujarat, India. This approval allows Zydus to enter the Canadian pharmaceutical market, potentially increasing its global presence and revenue while providing Canadian patients with an additional treatment option.
17Oct 25
Zydus Healthcare Faces Rs 2.17 Million Tax Demand from CGST Authority
Zydus Healthcare Limited, a subsidiary of Zydus Life Science, has received a tax demand order of Rs 2.17 million from the Assistant Commissioner of CGST, Cuttack-I Division, Odisha. The order covers disallowed Input Tax Credit and short payment of tax under the Reverse Charge Mechanism for April 2018 to March 2023. An equal penalty amount has been imposed. Zydus Healthcare intends to challenge the order through an appeal, stating there is no material financial impact on either the subsidiary or the parent company. The company disclosed this information to stock exchanges on October 17, 2023, in compliance with SEBI regulations.
06Oct 25
Zydus Lifesciences Secures Regulatory Approvals in North America
Zydus Life Science has received USFDA approval for Deflazacort oral suspension (22.75 mg/mL) for treating Duchenne Muscular Dystrophy in patients 5 years and older. The product will be manufactured in Italy. This approval brings Zydus's total USFDA approvals to 424, with 487 ANDAs filed since FY 2003-04. Additionally, Zydus obtained Health Canada approval for Liothyronine tablets in 5 mcg and 25 mcg strengths, expanding its presence in the North American pharmaceutical market.
01Oct 25
Zydus Lifesciences Receives FDA Complete Response Letter for CUTX-101 Drug Application
Sentynl Therapeutics, a U.S. subsidiary of Zydus Life Science, received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for CUTX-101, a treatment for Menkes disease. The CRL focuses on manufacturing concerns, specifically the need for a CGMP inspection of the production facility. Zydus has already responded to the FDA's re-inspection, demonstrating CGMP compliance. CUTX-101 is a subcutaneous injectable formulation of copper histidinate designed to treat Menkes disease, a rare genetic disorder affecting copper absorption. The company plans to request a meeting with the FDA to discuss the CRL and resubmission of the NDA.
25Sept 25
Zydus Lifesciences Gets ₹35.90 Crore Tax Demand Dropped, ₹3.35 Crore Liability Confirmed
Zydus Lifesciences announced that CGST authorities have dropped tax demands worth ₹35.90 crore out of a total ₹39.25 crore. A liability of ₹3.35 crore plus interest and penalty remains, related to CENVAT credit on sales commission paid to foreign entities. The company plans to appeal this remaining demand. Zydus states there is no material financial impact on its operations from the confirmed liability. Shares of Zydus Lifesciences closed at ₹1,018.90, down 1.57%.
21Sept 25
Zydus Lifesciences' Ahmedabad Oncology Facility Receives Improved FDA Classification
Zydus Lifesciences' oncology injectable manufacturing facility in Ahmedabad has received an improved classification from the U.S. FDA. The facility's status has been upgraded from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI) following a GMP follow-up inspection in June 2025. This change indicates that while some issues were found, they can be addressed through voluntary action, potentially allowing for smoother operations and increased production. The company officially disclosed this development to stock exchanges on September 21, 2025.
15Sept 25
Zydus Lifesciences' ZyVet Launches First Generic Veterinary Medications for Canine Urinary Incontinence and Heart Care
Zydus Life Science's subsidiary, ZyVet Animal Health, has introduced two generic medications for pets: the first FDA-approved generic phenylpropanolamine hydrochloride tablets for canine urinary incontinence and generic Furosemide tablets for managing congestive heart failure in dogs and cats. These cost-effective alternatives aim to improve pet care accessibility and affordability. The company emphasizes the importance of removing cost barriers to compassionate care and providing high-quality treatment options for all pets.
08Sept 25
Zydus Lifesciences' Jarod Injectable Plant Receives 4 Observations in USFDA Inspection
Zydus Lifesciences announced that a recent USFDA inspection of its Jarod injectable plant concluded with four observations. The company emphasized that no data integrity issues were identified during the inspection. This outcome suggests that the company's manufacturing practices largely align with USFDA standards, and the limited number of observations may allow for prompt resolution. The inspection's results are significant for Zydus Lifesciences' regulatory compliance efforts and its operations in the U.S. pharmaceutical market.
05Sept 25
Zydus Lifesciences Concludes INR 600 Crore Share Buyback with 8.66 Times Oversubscription
Zydus Lifesciences has concluded its share buyback program, repurchasing 59,70,149 equity shares at INR 1,005 per share, totaling INR 599.99 crore. The offer was oversubscribed by 8.66 times, with 45,308 valid bids received for 5,16,87,188 shares. The buyback period ran from February 29 to March 6, 2024, with settlement on March 14. Post-buyback, the company's paid-up share capital will decrease from 101,22,04,139 to 100,62,33,990 shares. The Zydus Family Trust was the largest participant, accounting for 64.53% of repurchased shares.
05Sept 25
Zydus Lifesciences Bolsters Management Team with Appointment of Nitin D. Parekh as President (Special Projects)
Zydus Lifesciences Limited has appointed Nitin D. Parekh as President (Special Projects) for a two-year term starting September 8, 2025. Parekh, 64, brings over 40 years of experience in finance, strategy, legal, and IT sectors. He previously served as the company's CFO for more than 16 years. The appointment aims to strengthen the management team amid growing business complexity. Parekh's expertise in M&A, negotiations, and capital structure design is expected to contribute to the company's future growth.
04Sept 25
Zydus Lifesciences and Synthon Forge Alliance for Generic Ozanimod in U.S. Market
Zydus Lifesciences' subsidiary has entered an exclusive licensing agreement with Synthon BV for generic Ozanimod capsules in the U.S. Synthon will handle regulatory approval and manufacturing, while Zydus will commercialize the product. The total addressable market for Ozanimod in the U.S. is approximately $637 million. Synthon's first-filer status grants potential 180-day shared exclusivity. Ozanimod treats multiple sclerosis and ulcerative colitis. This partnership aims to expand access to affordable treatment options.
03Sept 25
Zydus Lifesciences May Benefit from Potential GST Exemption on Cancer Medications
The Indian government is considering exempting cancer medications from GST, which could positively impact Zydus Lifesciences. This policy change may make cancer drugs more affordable and accessible, potentially increasing demand for Zydus's oncology products. The company could see increased sales volumes and market share in the cancer treatment sector. Zydus recently launched VaxiFlu™, India's first trivalent influenza vaccine, showcasing its innovation in healthcare.
02Sept 25
Zydus Lifesciences Launches VaxiFlu™: India's First Trivalent Influenza Vaccine
Zydus Lifesciences has introduced VaxiFlu™, India's first trivalent influenza vaccine, aligning with WHO's latest recommendations. The vaccine incorporates updated strains for optimal protection against current influenza variants. VaxiFlu™ is recommended for individuals aged 6 months and above, addressing a global health concern that causes 3-5 million severe illnesses annually.
29Aug 25
Zydus Lifesciences' Saroglitazar Shows Promise in Primary Biliary Cholangitis Trial
Zydus Life Science reported positive results from its Epic-III Phase 2(B)/3 clinical trial of Saroglitazar Magnesium for Primary Biliary Cholangitis (PBC) treatment. The trial demonstrated a 48.50% biochemical response rate. The company plans to submit for regulatory approval in Q1 2026, potentially offering a new treatment option for this progressive liver disease.
20Aug 25
Zydus Lifesciences Reports 6% Revenue Growth in Q1, Driven by Strong Performance Across Key Markets
Zydus Lifesciences posted consolidated revenues of ₹65.70 billion in Q1 FY2024, up 6% year-on-year. EBITDA reached ₹20.90 billion with a 31.8% margin. Net profit increased 3% to ₹14.70 billion. US Formulations revenue grew 3% to ₹31.80 billion. India Geography saw 6% overall growth, with branded formulations outpacing the market at 9%. International markets' formulations business grew 37% to ₹7.30 billion. The company completed strategic acquisitions and partnerships, including Amplitude Surgical and Braile Biomedica. Zydus maintains its guidance for single-digit growth in the US market and expects strong double-digit growth in international markets for the fiscal year.
13Aug 25
Zydus Lifesciences Completes USFDA Inspection Successfully, Projects Single-Digit US Growth
Zydus Life Science has successfully completed a USFDA inspection at its Ahmedabad facility with no issues identified. The company projects single-digit growth for its US business with EBITDA margins exceeding 26%. In contrast, international markets are expected to see high-teens to mid-20s percentage growth. Zydus plans to launch over 30 new products in the US, including Ibrance. The company reported a 5.9% YoY increase in total revenue to ₹65,737.00 million, with EBITDA at ₹20,885.00 million. Zydus continues to invest heavily in R&D, spending ₹4,856.00 million or 7.4% of revenues. The company has also completed strategic acquisitions to expand its global footprint.
12Aug 25
Zydus Lifesciences Posts Robust Q1 Results with 6% Revenue Growth
Zydus Life Science's Q1 FY24 consolidated revenue increased by 5.9% to ₹65,737.00 million, with net profit rising 3.3% to ₹14,668.00 million. The India Formulations business grew 8%, US Formulations 2.9%, and International Markets 36.8%. The company maintained an EBITDA margin of 31.8% and provided future guidance of 26%. R&D expenses were ₹4,856.00 million, representing 7.4% of total revenues. The company launched three new products in the US market and received approvals for six ANDAs.
11Aug 25
Zydus Lifesciences Secures USFDA Approval for Diltiazem Hydrochloride Tablets
Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration (USFDA) for its Diltiazem Hydrochloride Tablets. This approval allows the company to market and distribute the medication in the United States. Diltiazem Hydrochloride, a calcium channel blocker, is used to treat hypertension, angina, and certain arrhythmias. The approval is expected to strengthen Zydus Lifesciences' position in the U.S. pharmaceutical market and potentially open new revenue streams.
29Jul 25
Zydus Lifesciences Acquires 85.6% Stake in France's Amplitude Surgical for €256.8 Million
Zydus Life Science has completed the acquisition of an 85.6% stake in Amplitude Surgical SA, a French orthopedic surgical technology firm, for €256.8 million. The deal, executed through Zydus MedTech (France) SAS, was finalized on July 29, 2025, at €6.25 per share. A mandatory tender offer for remaining shares will be filed, with Zydus aiming to hold over 90% of Amplitude's capital. Olivier Jallabert will continue as CEO of Amplitude Surgical. This acquisition expands Zydus's global footprint in the orthopedic market and enhances its healthcare portfolio.
16Jul 25
Zydus Lifesciences Secures FDA Approval for Celecoxib Capsules, Expanding Pain Management Portfolio
Zydus Lifesciences has obtained final FDA approval for Celecoxib Capsules in 50 mg, 100 mg, 200 mg, and 400 mg strengths. This generic version is equivalent to Celebrex® Capsules, used for pain management. Celecoxib, an NSAID, treats conditions like arthritis and menstrual pain. The U.S. market for Celecoxib capsules was $122.60 million annually. Zydus will manufacture the capsules at its Ahmedabad facility. This approval adds to Zydus's 428 total FDA approvals and 492 ANDA filings.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
CiplaZydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,803.70
(+0.25%)
6,671.00
(+0.06%)
4,415.50
(+0.11%)
1,406.30
(+0.38%)
1,107.00
(+2.72%)
1,303.80
(+0.02%)
2,266.70
(-0.04%)
2,364.00
(-0.49%)
1,440.30
(+0.97%)
1,391.80
(+2.19%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
